
COYA Stock Forecast & Price Target
COYA Analyst Ratings
Bulls say
Coya Therapeutics is a clinical-stage biotechnology company with key programs focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases. Their recent publication showcasing the link between biomarkers and disease progression and survival in Amyotrophic Lateral Sclerosis (ALS) provides strong validation for their approach and supports the ongoing randomized ALSTARS trial. With updates planned for their lead asset COYA 302 in ALS and FTD, alongside clinical milestones and enrolling trials, Coya appears to be progressing towards a solid clinical development story that could de-risk the lead asset.
Bears say
Coya Therapeutics is facing several key risks, including clinical and regulatory risk, partnership risk, financial risk, commercial risk, and legal and intellectual property risk. While the recent publication in Brain Communications strengthens the company's scientific thesis and adds validation to their platform, it does not have a significant impact on near-term financial estimates. However, with milestones in clinical trials and sales, the company has the potential to grow in the future, but these risks should be carefully considered. Overall, the company's current outlook is negative due to the high level of risk involved and the lack of near-term financial impact from recent developments.
This aggregate rating is based on analysts' research of Coya Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
COYA Analyst Forecast & Price Prediction
Start investing in COYA
Order type
Buy in
Order amount
Est. shares
0 shares